Ken Griffin Eye Point Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$7.58 - $10.54 $70,494 - $98,021	-9,300 Reduced 9.35%	90,200 $720,000
Q2 2024 Aug 14, 2024	BUY	$8.16 - $22.89 $34,272 - $96,138	4,200 Added 4.41%	99,500 $865,000
Q1 2024 May 15, 2024	SELL	$19.93 - $29.71 $8.04 Million - $12 Million	-403,500 Reduced 80.89%	95,300 $1.97 Million
Q4 2023 Feb 14, 2024	BUY	$5.71 - $24.13 $2.52 Million - $10.6 Million	441,100 Added 764.47%	498,800 $11.5 Million
Q3 2023 Nov 14, 2023	BUY	$7.99 - $15.36 $357,952 - $688,128	44,800 Added 347.29%	57,700 $461,000
Q2 2023 Aug 14, 2023	BUY	$3.03 - $9.0 $24,846 - $73,800	8,200 Added 174.47%	12,900 $112,000
Q1 2023 May 15, 2023	SELL	$2.28 - $5.04 $9,804 - $21,672	-4,300 Reduced 47.78%	4,700 $13,000
Q4 2022 Feb 14, 2023	SELL	$2.37 - $7.2 $27,255 - $82,800	-11,500 Reduced 56.1%	9,000 $31,000
Q3 2022 Nov 14, 2022	BUY	$6.96 - $11.12 $16,704 - $26,687	2,400 Added 13.26%	20,500 $162,000

150

58M

177K

263K

Ticker EYPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,072,200
Market Cap $302M
Description
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.